The inhibition of the NF-κB signalling pathway has been shown to increase cancer cell responsiveness to anti-cancer therapies, further highlighting the potential benefit of FLX and PER among individuals with breast cancer [40]. The gene discussed is NFKB1; the disease is breast carcinoma.